Sponsor: IVY
Sponsor Study ID: P3-24-021
Study Title: A Phase 3, Open-Label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly Diagnosed, MGMT Unmethylated Glioblastoma
CTO #: 104096
NCT Number: NCT06388733
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Brain and Nervous System
Study Objectives: Test whether niraparib compared with temozolomide significantly extends progression-free survival in participants with newly-diagnosed, MGMT promoter unmethylated glioblastoma. Test whether niraparib compared with temozolomide significantly extends overall survival in participants with newly-diagnosed, MGMT promoter unmethylated glioblastoma.